Tamoxifen

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients

Functional polymorphisms in xenobiotic metabolizing enzymes and therapy of breast cancer

Association of CYP2D6 and CYP2C19 polymorphisms and disease

Genetic polymorphisms of cytochrome P450D6

An overview on the allelic variant of CYP2D6 genotype

FDA-label Tamoxifen 2011

Pharmacogenetics and breast cancer endocrine therapy

Tamoxifen pharmacogenomics-the role of CYP2D6 as a predictor of drug response

Genotype-guided Tamoxifen dosing increases active metabolite exposure in

Tamoxifen metabolite concentrations CYP2D6 and breast cancer outcomes

Evaluation of CYP2D6 and efficacy of Tamoxifen and raloxifene

Clinical relevance of CYP2D6 genetics for Tamoxifen response in breast cancer

Pharmacogenomics of Tamoxifen therapy

CYP2D6 genotype antidepressant use and Tamoxifen metabolism during adjuvant breast cancer treatment

Regresar al Acervo